Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Heading up now but needs to increase by 50+% in order to cover 35% drop.
Ditto. We first arrived at this level in August 2017. Tempted to use some precious firepower and top up. Seems a crazy drop. This is one share that shouldn't be falling, yet it's down 35%.
when this should be doing well. Hopefully a statement from the company will be forthcoming if the falls continue. Shocked to see falls follow falls though my faith is unshaken here.
If you look at the modeling the government are using, the change in strategy from mitigation to suppression means that the end point now becomes a (hoped for) vaccine in 12-18 months. It is hard to see the adherence to the 'rules' for this long, so in practice it is likely to end up being somewhere between the two strategies. It should be good for Trist but the economic cost is going to be immense and impact on everyone for many years ahead.
It is hard to measure how many will die because of the economic consequences - both direct because of health issues from having no work and indirect because of fewer resource going forward for social care , cancer research etc. You have to wonder if these will eventually exceed the numbers of those who would have died from a 'mitigation strategy' - trouble is that there is no simple model or 'test' for these. Sorry if rather maudlin , but I have heard of so many local companies already talking of large numbers of redundancies and we are still only at the start of this.
That was my interpretation as well, used it as an opportunity to buy some more.
From looking at share activity today, there was a fair amount of selling early on and very little activity (and at small amounts) after lunch. Other than people who exit through stop losses, I suspect that most holders are hanging on to what they have and so the market is drying up and the sp is being dragged down by small trades.
Any reason?
It is anecdotal rather than a reliable stat, but there is a story in The Times Business section today about a very small Maidenhead company called Big Wipes, which apparently sells to the trade across Europe. It is apparently a basic cleaning product, but with no evidence (or claim) that it has any impact on the virus. The report goes on to say that the company's distributors have run out of stock in Scandinavia, France and Germany. I am expecting many more similar stories. Of course, TSTL mainly targets hospitals, where standards(and so barriers to entry) are much higher. And TSTL's global footprint is considerably larger. What is happening is going to pose some real challenges for TSTL, but I think that the company will inevitably need to gear up.
I am assuming that in the next few weeks (and maybe even sooner) TSTL will issue a trading update. If that happens, I cannot see that it will say other than that they have had to materially ramp up production across the board. We were told at the last presentation (I asked the obvious question), that they could increase production at least three-fold. Why would they not be flat out at the moment?
Grim times, but at least they have a range of products that do good and protect people. That is paramount.
Will we expect to see the herd jump on here in the next 2-4 weeks?..
Coronavirus outbreak has led to an emergency “special exemption” order from China and prompted “substantial” extra purchases by the NHS.
Https://maynardpaton.com/2020/02/29/tristel-management-reveals-extra-nhs-and-chinese-orders-to-combat-coronavirus-after-h1-uk-sales-advance-a-superb-14/
The Tristel story began in 1993 when the founding shareholders developed a proprietary chlorine dioxide formulation to be used for the disinfection of flexible endoscopes to replace glutaraldehyde. At the time, glutaraldehyde was used universally throughout hospitals in the United Kingdom, and indeed worldwide, for the disinfection of heat sensitive medical instruments. However, it was known to be toxic.
During the following decade Tristel captured significant market share in the United Kingdom hospital market. In June 2005 Tristel plc was listed on the London Stock Exchange AIM market.
By this time the Company had developed a broader vision for the use of its chlorine dioxide chemistry and had developed products for the disinfection of a wide range of non-lumened and single lumened endoscopes and ultrasound probes, and also the disinfection of surfaces in hospitals.
A key milestone in Tristel’s development was the establishment of its manufacturing plant in Cambridgeshire in 2007. The company is compliant to the new versions of the following standards,ISO13485:2016 and ISO9001:2015, MDSAP.Today, Tristel serves the disinfection requirements of veterinary practices via its Anistel product range and those of clean rooms in healthcare and the life sciences industry via its Crystel product range. The Company operates a Class 6 cleanroom to manufacture sterile-packed disinfectant products.
The Company has subsidiaries in Germany, Poland, Switzerland, Belgium, Netherlands, France, Italy, Russia, Hong Kong, China, Australia, New Zealand, Japan and USA, and sells its products via distributors in more than thirty other countries
They supply to a large number of countries in Europe including Italy, and also to China.
We know that they were upping supplies to the NHS and shipped some to China, but it is hard to know how much extra this all amounts to, 10%,50% , 100% increase in sales?
Slow to rise but the next two weeks are going to be interesting for this share when the CV trajectory in UK follows other countries ..
The problems causing this fall will continue for quite some time, and may get much worse. They may cause other problems: for example they have already caused the oil-price to collapse, and a recession now looks quite likely. There could be more. I think everything could have further to fall, and when things begin to recover it will not be quick. TSTL being what it is makes things even more complicated here. I agree it’s the last share you would expect to have seen fall.
IMO, of course. DYOR: or rather MYOG - Make Your Own Guess. That’s really what it feels like: experienced guesswork.
Take care everyone, and all the best.
recent gains wiped out and not by one of their products. The whole market has caught a cold and the falls are celarly infectious even to shares like Tstl which should thrive in this environment. Time to dudt down my cash account and channel some in here. COV19 is masking all the good news in the share.
This Thursday's 'Shares' magazine gives Tristel a strong rating, also repeated in the Sunday papers. Doesn't seem to affect SP.
Hopefully the price will stick this this time, I was surprised that anyone was selling this around 430 last week.
The FDA have said/been told to fast track Covid 19 vaccines/tests /therapeutics hopefully they may also expediate the progress of Tristel's products in the same way that China did.
on Cov 19 is finding its legs again. The rise is no surprise really and once this goes through 500p we are sure to head to 550p over the next months. The USA is still not in the price.
On the rise again. No wonder, I suppose. Lord...!
I see the directors have been altering their holdings/cashing in a little. Can't blame Paul Barnes with nearly £2m worth in one stock. Bought a nice car? But in the main they're holding.
Shares in infection prevention specialist Tristel (TSTL) surged this week, as strong first half trading and another bullish outlook reminded investors that at least one Aim-listed company is benefiting from the ascent of viral threats to the top of the global risk agenda.
TSTL:LSE
Tristel PLC
1mth
Today change
1.10%
Price (GBP)
460.00
The group has been careful not to overplay its exposure to Covid-19. Instead, management used half-year figures to suggest the virus “will be a powerful influence on global healthcare systems for greater investment in infection prevention and control”.
Nonetheless, fast-tracked orders from the Chinese military and stockpiling by UK hospitals suggest 2020 will build on a strong six months to December, when overseas sales jumped 30 per cent, pre-tax profit rose a quarter, and the gross margin ticked up to 79 per cent. Domestic sales were also robust, thanks to increased use of diagnostic tools in secondary care facilities and revamped infection control procedures.
House broker Finncap left its adjusted earnings forecasts unchanged at 11.7p per share for the year to June 2020, and 12.5p in FY2021.
IC View
Finncap also sees a free cash flow yield of 3.5 per cent for FY2021 as fair value for the stock. That’s a chunky 120 basis points below the median market yield. The shares have re-rated since our original tip (73.5p, 23 Apr 2015), but forecasts look light, the US remains an enormous prospect, and we still think pharma groups would pay up for Tristel’s unrivalled proprietary technology. Buy at 441p.
Last IC View: Buy, 304p, 17 Oct 2019
Agreed. A lot of shares have rallied following the rout this morning, with buy volumes greater than sales, in spite of the fall in the share price. But I think the news will get worse and at that point those who have bought in today or earlier will not buy again. So I am afraid there is further to fall for the general market, and more grief for everyone.... while Tristel will continue its rise. My guess.
their day and I expect Tristel to move back towards 500p in short order. Tstl is a contra indicator for the current market anyway. If the COV19 virus spreads to Europe more rapidly then thought the general market will be hammered it is actually good news for TSTL in strictly business terms. Some forth has been blown off and the SP can drive on from here.
Investors Chronicle is saying Buy. Article released today.
i was thinking of selling last week because of the PE glad I never. More than makes up for my other shares having a bit of pull back.
Wonder where we will be at the end of the week? Next stop who knows where. Give Elon a shout.
Yes; I agree that webinars are very useful, but they tend to be the preserve of the larger listed companies, rather than fairly small companies on AIM.It may be down to cost. The only small AIM co I know that does this sort of thing (there may be others) is Judges Scientific (JDG) in relation to their briefing to analysts. TSTL is much more user friendly than most - morning and evening briefing sessions for shareholders of interim and final results, plus a well attended shareholder day at their Snailwell HQ each July. On top of that, Finncap (house broker) is one of the few brokers who give wide access to their briefing notes, the latest of which came out yesterday.